These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24598449)

  • 1. A novel murine T-cell receptor targeting NY-ESO-1.
    Rosati SF; Parkhurst MR; Hong Y; Zheng Z; Feldman SA; Rao M; Abate-Daga D; Beard RE; Xu H; Black MA; Robbins PF; Schrump DA; Rosenberg SA; Morgan RA
    J Immunother; 2014 Apr; 37(3):135-46. PubMed ID: 24598449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
    Zhao Y; Zheng Z; Robbins PF; Khong HT; Rosenberg SA; Morgan RA
    J Immunol; 2005 Apr; 174(7):4415-23. PubMed ID: 15778407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
    Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
    Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
    Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.
    Sommermeyer D; Conrad H; Krönig H; Gelfort H; Bernhard H; Uckert W
    Int J Cancer; 2013 Mar; 132(6):1360-7. PubMed ID: 22907642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.
    McCormack E; Adams KJ; Hassan NJ; Kotian A; Lissin NM; Sami M; Mujić M; Osdal T; Gjertsen BT; Baker D; Powlesland AS; Aleksic M; Vuidepot A; Morteau O; Sutton DH; June CH; Kalos M; Ashfield R; Jakobsen BK
    Cancer Immunol Immunother; 2013 Apr; 62(4):773-85. PubMed ID: 23263452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
    Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
    Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of NY-ESO-1
    Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
    Front Immunol; 2021; 12():644520. PubMed ID: 33833762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
    Wargo JA; Robbins PF; Li Y; Zhao Y; El-Gamil M; Caragacianu D; Zheng Z; Hong JA; Downey S; Schrump DS; Rosenberg SA; Morgan RA
    Cancer Immunol Immunother; 2009 Mar; 58(3):383-94. PubMed ID: 18677478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
    Poncette L; Chen X; Lorenz FK; Blankenstein T
    J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
    Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
    PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
    Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
    Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1.
    Qiu CX; Bai XF; Shen Y; Zhou Z; Pan LQ; Xu YC; Zhao WB; Chen SQ
    Bioconjug Chem; 2020 Dec; 31(12):2767-2778. PubMed ID: 33237767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
    Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
    Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
    Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
    Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
    Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
    Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
    Ishihara M; Kitano S; Kageyama S; Miyahara Y; Yamamoto N; Kato H; Mishima H; Hattori H; Funakoshi T; Kojima T; Sasada T; Sato E; Okamoto S; Tomura D; Nukaya I; Chono H; Mineno J; Kairi MF; Diem Hoang Nguyen P; Simoni Y; Nardin A; Newell E; Fehlings M; Ikeda H; Watanabe T; Shiku H
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.
    Maruta M; Ochi T; Tanimoto K; Asai H; Saitou T; Fujiwara H; Imamura T; Takenaka K; Yasukawa M
    Sci Rep; 2019 Sep; 9(1):13293. PubMed ID: 31527633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.